690 related articles for article (PubMed ID: 31866476)
1. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy.
Tewari D; Patni P; Bishayee A; Sah AN; Bishayee A
Semin Cancer Biol; 2022 May; 80():1-17. PubMed ID: 31866476
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
Narayanankutty A
Curr Top Med Chem; 2021; 21(20):1816-1831. PubMed ID: 34279200
[TBL] [Abstract][Full Text] [Related]
3. The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds.
Roy T; Boateng ST; Uddin MB; Banang-Mbeumi S; Yadav RK; Bock CR; Folahan JT; Siwe-Noundou X; Walker AL; King JA; Buerger C; Huang S; Chamcheu JC
Cells; 2023 Jun; 12(12):. PubMed ID: 37371141
[TBL] [Abstract][Full Text] [Related]
4. Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
Narayanankutty A
Recent Pat Anticancer Drug Discov; 2020; 15(3):188-199. PubMed ID: 32914720
[TBL] [Abstract][Full Text] [Related]
5. The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances.
Khorasani ABS; Hafezi N; Sanaei MJ; Jafari-Raddani F; Pourbagheri-Sigaroodi A; Bashash D
Cell Biochem Funct; 2024 Apr; 42(3):e3998. PubMed ID: 38561964
[TBL] [Abstract][Full Text] [Related]
6. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
Shorning BY; Dass MS; Smalley MJ; Pearson HB
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
[TBL] [Abstract][Full Text] [Related]
7. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
8. Natural products attenuate PI3K/Akt/mTOR signaling pathway: A promising strategy in regulating neurodegeneration.
Fakhri S; Iranpanah A; Gravandi MM; Moradi SZ; Ranjbari M; Majnooni MB; Echeverría J; Qi Y; Wang M; Liao P; Farzaei MH; Xiao J
Phytomedicine; 2021 Oct; 91():153664. PubMed ID: 34391082
[TBL] [Abstract][Full Text] [Related]
9. Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents.
Sun H; Wang Z; Yakisich JS
Anticancer Agents Med Chem; 2013 Sep; 13(7):1048-56. PubMed ID: 23293890
[TBL] [Abstract][Full Text] [Related]
10. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
11. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
Yu L; Wei J; Liu P
Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.
Huang J; Chen L; Wu J; Ai D; Zhang JQ; Chen TG; Wang L
J Med Chem; 2022 Dec; 65(24):16033-16061. PubMed ID: 36503229
[TBL] [Abstract][Full Text] [Related]
13. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
14. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
17. PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer.
Zhu K; Wu Y; He P; Fan Y; Zhong X; Zheng H; Luo T
Cells; 2022 Aug; 11(16):. PubMed ID: 36010585
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PI3K/Akt/mTOR signaling by natural products.
Huang S
Anticancer Agents Med Chem; 2013 Sep; 13(7):967-70. PubMed ID: 23272914
[No Abstract] [Full Text] [Related]
19. Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy.
Chamcheu JC; Roy T; Uddin MB; Banang-Mbeumi S; Chamcheu RN; Walker AL; Liu YY; Huang S
Cells; 2019 Jul; 8(8):. PubMed ID: 31370278
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials.
Davoodi-Moghaddam Z; Jafari-Raddani F; Delshad M; Pourbagheri-Sigaroodi A; Bashash D
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15293-15310. PubMed ID: 37594532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
